| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 34.05% | BMO Capital | $21 → $20 | Maintains | Outperform |
| 05/22/2023 | 34.05% | BMO Capital | $18 → $20 | Upgrades | Market Perform → Outperform |
| 04/26/2023 | 20.64% | BMO Capital | $20 → $18 | Maintains | Market Perform |
| 04/25/2023 | 34.05% | Baird | $21 → $20 | Maintains | Outperform |
| 07/27/2022 | 40.75% | BMO Capital | $18 → $21 | Maintains | Market Perform |
| 07/26/2022 | 87.67% | Baird | $36 → $28 | Maintains | Outperform |
| 05/26/2022 | 34.05% | BMO Capital | → $20 | Downgrades | Outperform → Market Perform |
| 04/27/2021 | 54.16% | Credit Suisse | $19 → $23 | Maintains | Neutral |
| 04/27/2021 | 94.37% | Baird | $21 → $29 | Upgrades | Neutral → Outperform |
| 02/04/2021 | 27.35% | Credit Suisse | $16 → $19 | Maintains | Neutral |
| 11/23/2020 | 60.86% | BMO Capital | → $24 | Upgrades | Market Perform → Outperform |
| 10/27/2020 | 7.24% | Credit Suisse | $13 → $16 | Maintains | Neutral |
| 10/01/2020 | 7.24% | Sidoti & Co. | $14 → $16 | Maintains | Neutral |
| 07/21/2020 | — | Northcoast Research | Upgrades | Neutral → Buy | |
| 05/06/2020 | 7.24% | Baird | $17 → $16 | Maintains | Neutral |
| 05/01/2020 | — | Sidoti & Co. | Downgrades | Buy → Neutral | |
| 04/20/2020 | 0.54% | BMO Capital | $20 → $15 | Maintains | Market Perform |
| 03/17/2020 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 02/13/2020 | 34.05% | Sidoti & Co. | $22 → $20 | Maintains | Neutral |
| 04/30/2019 | 74.26% | Baird | $27 → $26 | Maintains | Neutral |
| 02/11/2019 | 60.86% | BMO Capital | $26 → $24 | Maintains | Market Perform |
| 11/06/2018 | 67.56% | Credit Suisse | $31 → $25 | Maintains | Neutral |
| 08/10/2018 | 107.77% | Credit Suisse | → $31 | Initiates Coverage On | → Neutral |
What is the target price for TrueBlue (TBI)?
The latest price target for TrueBlue (NYSE: TBI) was reported by BMO Capital on July 26, 2023. The analyst firm set a price target for $20.00 expecting TBI to rise to within 12 months (a possible 34.05% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TrueBlue (TBI)?
The latest analyst rating for TrueBlue (NYSE: TBI) was provided by BMO Capital, and TrueBlue maintained their outperform rating.
When is the next analyst rating going to be posted or updated for TrueBlue (TBI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TrueBlue, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TrueBlue was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
Is the Analyst Rating TrueBlue (TBI) correct?
While ratings are subjective and will change, the latest TrueBlue (TBI) rating was a maintained with a price target of $21.00 to $20.00. The current price TrueBlue (TBI) is trading at is $14.92, which is out of the analyst's predicted range.
